Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) EBITDA Margin (2018 - 2025)

TransMedics has reported EBITDA Margin over the past 8 years, most recently at 13.23% for Q4 2025.

  • Quarterly results put EBITDA Margin at 13.23% for Q4 2025, up 613.0% from a year ago — trailing twelve months through Dec 2025 was 17.93% (up 944.0% YoY), and the annual figure for FY2025 was 17.93%, up 944.0%.
  • EBITDA Margin for Q4 2025 was 13.23% at TransMedics, down from 16.2% in the prior quarter.
  • Over the last five years, EBITDA Margin for TMDX hit a ceiling of 23.24% in Q2 2025 and a floor of 216.61% in Q3 2021.
  • Median EBITDA Margin over the past 5 years was 3.38% (2023), compared with a mean of 32.25%.
  • Biggest five-year swings in EBITDA Margin: tumbled -15879bps in 2021 and later surged 19502bps in 2022.
  • TransMedics' EBITDA Margin stood at 132.57% in 2021, then skyrocketed by 84bps to 21.61% in 2022, then surged by 115bps to 3.21% in 2023, then skyrocketed by 122bps to 7.11% in 2024, then skyrocketed by 86bps to 13.23% in 2025.
  • The last three reported values for EBITDA Margin were 13.23% (Q4 2025), 16.2% (Q3 2025), and 23.24% (Q2 2025) per Business Quant data.